Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years Anxiety Attack has drawn increasing interest as a treatment for a range of neuropsychiatric disorders. The purpose of the current review is to determine CBD’s potential as a treatment for anxiety-related disorders, by assessing evidence from preclinical, human experimental, clinical, and epidemiological studies. We found that existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder when administered acutely; however, few studies have investigated chronic CBD dosing. Likewise, evidence from human studies supports an anxiolytic role of CBD, but is currently limited to acute dosing, also with few studies in clinical populations. Overall, current evidence indicates CBD has considerable potential as a treatment for multiple anxiety disorders, with need for further study of chronic and therapeutic effects in relevant clinical populations.
While we don’t normally think of anxiety as desirable, it’s actually a critical adaptive response that can help us cope with threats to our (or a loved one’s) safety and welfare. These responses help us recognize and avert potential threats; they can also help motivate us to take action to better our situation (work harder, pay bills, improve relationships, etc.). However, when we don’t manage these natural responses effectively, they can become maladaptive and impact our work and relationships. This can lead to clinically diagnosable anxiety-related disorders.
We’ve all heard the saying, “stress kills.” It’s true! Anxiety-related disorders affect a huge segment of our population—40 million adults (18%) in the United Statesage 18 and older. In response, Big Pharma has developed numerous drugs to treat anxiety-related disorders, from selective serotonin reuptake inhibitors (SSRIs) like Prozac and Zoloft to tranquilizers (the most popular class being benzodiazepines such as Valium and Xanax).